

K250553 Tomey Cornea/Anterior Segment OCT (CASIA2)Jul 18, 2025
143 days to decisionK250553 · Product code: **OBO** · Ophthalmic
Source: <https://www.510kdatabase.net/k250553/>**SUBMISSION DETAILS**

| | |
|-----------------------|-------------------------------------|
| Decision | Substantially Equivalent (Cleared) |
| Submission type | Traditional |
| Device classification | Tomography, Optical Coherence (OBO) |
| Date received | Feb 25, 2025 |
| Decision date | Jul 18, 2025 |
| Days to decision | 143 days |
| Third-party review | No |
| Combination product | No |
| PCCP authorized | No |
| Summary / Statement | Summary |

APPLICANT

| | |
|----------------|---------------------------------------|
| Company | Tomey Corporation |
| Location | Tokyo, JP |
| Contact | Yuko Matsushita |
| 510(k) history | 5 submissions · 5 cleared · 2008-2025 |

REGULATORY CONSULTANT

| | |
|-----------------|------------------|
| Consulting firm | Ora, Inc. |
| Contact | Roger Albright |

Regulatory consulting firm that managed this 510(k) submission on behalf of the applicant. Source: FDA accessdata.fda.gov

CLINICAL EVIDENCE - NCT06065072**Comparative Study of the Tomey OA-2000, Tomey CASIA2, and the LenStar LS900**

| | |
|-------------------|---|
| Status | Unknown - <i>No results published to ClinicalTrials.gov</i> |
| Enrollment | 167 patients (estimated) |
| Study sites | 1 site |
| Condition studied | Cataract; Aphakic Eye; Pseudophakia |
| Study type | Observational |
| Completion date | Oct 31, 2023 |
| Sponsor | Tomey Corporation (Industry) |

Primary outcome**Agreement between the test devices and predicate device**Source: ClinicalTrials.gov / U.S. National Library of Medicine - clinicaltrials.gov/study/NCT06065072